Pharmacology

Ibutilide Fumarate (U70226E) is the fumarate salt form of ibutilide, a class III antiarrhythmic agent. Ibutilide exerts its effect by activating a slow, inward, predominately sodium current rather than by blocking outward potassium currents. This results in prolongation of atrial and ventricular action potential duration and refractory periods. Ibutilide slightly decreases the sinus rate and atrioventricular (AV) conduction and produces a dose-related prolongation of the QT interval.

NS3861 is an agonist of nicotinic acetylcholine receptors (nAChRs) that binds with high affinity to heteromeric α3β4 and α4β2 nAChRs, displaying β-subunit preference and no activation at α4-containing receptors. The maximal efficacy of NS3861 depends on the ligand-binding domain, and a serine to threonine substitution in the principal subunit may explain the lack of activation at α4-containing receptors.

Eticlopride, an antipsychotic, is a Selective dopamine D2/D3 receptor antagonist (Ki: 0.5/0.16 nM).

Tween 80 is a nonionic surfactant and emulsifier that reduces bacterial adherence and inhibits biofilm formation. Tween 80 is widely used as a co-solvent in pharmacology experiments because of its ability to enhance the solubility of compounds in the aqueous phase.

2-Methyl-4-nitroimidazole (2-MNI) is a heterocyclic compound with antimicrobial, anti-inflammatory, and antitumor activities.2-MNI has been used in a variety of fields including biochemistry, pharmacology, and biotechnology.

Isosteviol ((-)-Isosteviol), a common natural sweetener, belongs to tetracyclic diterpene glycosides. The pharmacology researches have suggested that stevioside and its hydrolysis products, steviol, isosteviol and steviolbioside, have many biological activities, such as reducing blood glucose, lowering blood pressure, anti-inflammation, anti-tumor, anti-diarrhea, antibacterium, immunoregulation, etc.

(R)-5-Oxopyrrolidine-2-carboxylic acid (D-Pyroglutamic acid) is a cyclic derivative of glutamic acid, physiologically present in mammalian tissues. It releases GABA from the cerebral cortex and exhibits anti-anxiety effects in a simple approach-avoidance conflict situation in rats. In clinical pharmacology experiments, it significantly shortens the plasma half-life of ethanol during acute intoxication.

TD-0212 is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).

TD-0212 TFA is an orally active dual pharmacology compound, functioning as an antagonist of the angiotensin II type 1 receptor (AT1) with a pKi of 8.9, and as an inhibitor of neprilysin (NEP) with a pIC50 of 9.2.

Cirazoline hydrochloride is a synthetic compound that acts as a competitive full agonist of the α1A-adrenergic receptor (α1A-AR) with a binding affinity of Ki = 120 nM, and Cirazoline hydrochloride also functions as a partial agonist at α1B-AR (Ki = 960 nM) and α1D-AR (Ki = 660 nM), thereby serving as a versatile adrenergic receptor probe with relevance for studying vascular tone regulation, adrenergic pharmacology, and potential therapeutic cardiovascular applications.

D-159404, as an allosteric inhibitor, demonstrates superior inhibitory effects on the full-length PDE 4D3 compared to its truncated form and exhibits higher cellular activity. This sets it apart from competitive inhibitors like roflumilast and cilomilast. These findings indicate that D-159404 and related compounds may offer valuable insights into PDE 4 pharmacology and serve as strong candidates for further study on cAMP signaling's impact on disease treatment.

S-Tenatoprazole sodium: A promising new proton pump inhibitor with favorable safety pharmacology characteristics.

CL-424032 is a defined pyrazolo[5-a]pyrimidine derivative that functions as a potent sodium channel inhibitor, effectively blocking sodium ion flux across cellular membranes. CL-424032 is extensively utilized in pharmacology and drug discovery research to investigate sodium channel–dependent excitability, signal propagation, and therapeutic modulation of ion channel activity.

(S,R,S)-AHPC-PEG2-NHS ester is a synthetic PROTAC linker that combines the E3 ligase ligand with a PEG linker to enhance PROTAC pharmacology. The NHS ester reacts with amine groups, and the hydrophilic PEG spacer increases water solubility.

Atoxifent is a μ-opioid receptor agonist (EC50=0.39 nM), found in brain regions involved in pain control, emotion, habit learning, and cognition. It exhibits potent analgesic effects with a lower risk of respiratory depression and is useful for research in opioid pharmacology and signal transduction.

2-Hydroxysaclofen is a potent γ-amino-butyric-acid-B receptor antagonist that effectively abolishes nicotine-induced hypolocomotor effects, enhances antinociceptive responses, and stimulates luteinizing hormone secretion in female rats, making it a valuable pharmacological probe for investigating GABAB receptor–mediated neuroendocrine regulation and behavioral pharmacology.

SDZ 205-557 hydrochloride is a selective 5-HT4 receptor antagonist that effectively blocks serotonin-mediated signaling, SDZ 205-557 hydrochloride is widely applied in neurological and gastrointestinal research to study 5-HT4 receptor function, neurotransmission modulation, cognitive processes, and receptor-specific pharmacology in both in vitro and in vivo experimental systems.

Setomimycin is a potent antibiotic compound that inhibits the SARS-CoV-2 main protease (Mpro) with an IC50 value of 12.02 μM, and also exhibits anti-inflammatory, antioxidant, antiproliferative, and antitumor activities, enabling multidisciplinary research spanning antiviral drug discovery, inflammation biology, and cancer pharmacology.

AHR-16329 can be used in ocular pharmacology.

Buthiazide (Butizide) is a diuretic compound commonly used in cardiovascular and renal research, particularly in studies focused on hypertension and fluid balance regulation, where Buthiazide was employed to investigate electrolyte transport, renal function, and blood pressure control mechanisms in both experimental and translational pharmacology settings.

CGP 31358 is a new chemical entity with a novel mechanism of action at the NMDA receptor, and as such may form a tool for understanding the molecular pharmacology of this receptor-channel complex. It binds to a site on the NMDA receptor that is coupled to

GSK256471 is a potent selective NK(3) antagonist that shows a high affinity for recombinant human (PK (I) value 8.9) and native guinea pig (PK (I) value 8.4) tachykinin NK(3) receptors. In vitro functional assessment showed that GSK256471 reduced the E(Ma

Neuromedin U-23 (NMU-23) is a neuropeptide involved in diverse biological processes, including smooth muscle contraction, energy homeostasis, and nociception.1It is an agonist of neuromedin-U receptor 1 (NMUR1; EC50= 0.17 nM for the human receptor in a calcium mobilization assay using HEK293 cells) and NMUR2 (EC50= ~1.4-2 nM for arachidonic acid release in CHO cells expressing the human receptor).2,3NMU-23 (1 μM) induces contractions in isolated rat colon smooth muscle strips.4It decreases body weight and food intake and increases core body temperature in mice when administered at a dose of 36 μg/animal.5Intrathecal administration of NMU-23 decreases the mechanical pain threshold in the von Frey test in rats.6 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBr. J. Pharmacol.158(1)87-103(2009) 2.Szekeres, P.G., Muir, A.I., Spinage, L.D., et al.Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3J. Biol. Chem.275(27)20247-20250(2000) 3.Hosoya, M., Moriya, T., Kawamata, Y., et al.Identification and functional characterization of a novel subtype of neuromedin U receptorJ. Biol. Chem.275(38)29528-29532(2000) 4.Brighton, P.J., Wise, A., Dass, N.B., et al.Paradoxical behavior of neuromedin U in isolated smooth muscle cells and intact tissueJ. Pharmacol. Exp. Ther.325(1)154-164(2008) 5.Peier, A., Kosinski, J., Cox-York, K., et al.The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2)Endocrinology150(7)3101-3109(2009) 6.Yu, X.H., Cao, C.Q., Mennicken, F., et al.Pro-nociceptive effects of neuromedin U in ratNeuroscience120(2)467-474(2003)

Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction.1Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated rolesin vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock.2,2NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction.3NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.4 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBritish Journal of Pharmacology15887-103(2009) 2.Greenwood, H.C., Bloom, S.R., and Murphy, K.G.Peptides and their potential role in the treatment of diabetes and obesityRev.Diabet.Stud.8(3)355-368(2011) 3.Mitchell, J.D., Maguire, J.J., Kuc, R.E., et al.Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular systemCardiovascular Research81353-361(2009) 4.Alfa, R.W., Park, S., Skelly, K.R., et al.Suppression of insulin production and secretion by a decretin hormoneCell Metabolism21(2)323-333(2015)